Chronic cyanosis and vascular function: Implications for patients with cyanotic congenital heart disease

Cardiology in the Young

Volumn 20, Issue 3, 2010, Pages 242-253

  Cordina, Rachael L ^a   Celermajer, David S ^a  

^a ROYAL PRINCE ALFRED HOSPITAL   (Australia)

Author keywords

Congenital heart disease; Cyanosis; Endothelial dysfunction; Erythrocytosis; Haemorheology

Indexed keywords

ANGIOTENSIN RECEPTOR ANTAGONIST; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; N(G) NITROARGININE METHYL ESTER; NITRIC OXIDE; ROSUVASTATIN;

ACUTE DISEASE; BLOOD VISCOSITY; CARDIOVASCULAR FUNCTION; CHRONIC DISEASE; CYANOSIS; CYANOTIC HEART DISEASE; DRUG MECHANISM; ENDOTHELIUM CELL; ERYTHROCYTE DEFORMABILITY; ERYTHROCYTOSIS; HEMATOCRIT; HUMAN; IRON DEFICIENCY; MICROCIRCULATION; NONHUMAN; PATHOPHYSIOLOGY; RETINA BLOOD FLOW; REVIEW; SCAVENGING SYSTEM; SHEAR STRESS; VASCULAR DISEASE; VASCULARIZATION; VASODILATATION; VENOUS THROMBOEMBOLISM; ANOXIA; BLOOD; COMPLICATION; CONGENITAL HEART MALFORMATION; DISEASE COURSE; PHYSIOLOGY; POLYCYTHEMIA; VASCULAR ENDOTHELIUM; VASCULAR SMOOTH MUSCLE; VASOCONSTRICTION;

ANOXIA; BLOOD VISCOSITY; CHRONIC DISEASE; CYANOSIS; DISEASE PROGRESSION; ENDOTHELIUM, VASCULAR; HEART DEFECTS, CONGENITAL; HUMANS; MICROCIRCULATION; MUSCLE, SMOOTH, VASCULAR; POLYCYTHEMIA; VASCULAR DISEASES; VASOCONSTRICTION;

EID: 77953606329     PISSN: 10479511     EISSN: 14671107     Source Type: Journal    
DOI: 10.1017/S1047951110000466     Document Type: Review

References (136)

1. Lerman A, Zeiher AM. Endothelial function: cardiac events. Circulation 2005; 111: 363-368.
2. Fischer D, Rossa S, Landmesser U, et al. Endothelial dysfunction in patients with chronic heart failure is independently associated with increased incidence of hospitalization, cardiac transplantation, or death. Eur Heart J 2005; 26: 65-69.
3. Engelfriet P, Boersma E, Oechslin E, et al. The spectrum of adult congenital heart disease in Europe: morbidity and mortality in a 5 year follow-up period. The Euro Heart Survey on adult congenital heart disease. Eur Heart J 2005; 26: 2325-2333.
4. Ammash N, Warnes CA. Cerebrovascular events in adult patients with cyanotic congenital heart disease. J Am Coll Cardiol 1996; 28: 768-772.
5. Daliento L, Somerville J, Presbitero P, et al. Eisenmenger syndrome. Factors relating to deterioration and death. Eur Heart J 1998; 19: 1845-1855.
6. Perloff JK, Hart EM, Greaves SM, Miner PD, Child JS. Proximal pulmonary arterial and intrapulmonary radiologic features of Eisenmenger syndrome and primary pulmonary hypertension. Am J Cardiol 2003; 92: 182-187.
7. Silversides CK, Granton JT, Konen E, Hart MA, Webb GD, Therrien J. Pulmonary thrombosis in adults with Eisenmenger syndrome. J Am Coll Cardiol 2003; 42: 1982-1987.
8. Niwa K, Perloff JK, Kaplan S, Child JS, Miner PD. Eisenmenger syndrome in adults: ventricular septal defect, truncus arteriosus, univentricular heart. J Am Coll Cardiol 1999; 34: 223-232.
9. Oechslin EN, Harrison DA, Connelly MS, Webb GD, Siu SC. Mode of death in adults with congenital heart disease. Am J Cardiol 2000; 86: 1111-1116.
10. Pirofsky B. The determination of blood viscosity in man by a method based on Poiseuille's law. J Clin Invest 1953; 32: 292-298.
11. Stuart J, Kenny MW. Blood rheology. J Clin Pathol 1980; 33: 417-429.
12. House SD, Lipowsky HH. Microvascular hematocrit and red cell flux in rat cremaster muscle. Am J Physiol 1987; 252 (Part 2): H211-H222.
13. Lipowsky HH, Firrell JC. Microvascular hemodynamics during systemic hemodilution and hemoconcentration. Am J Physiol 1986; 250 (Part 2): H908-H922.
14. Fahraeus R. The suspension stability of blood. Physiol Rev 1929; 9: 241-274.
15. Lipowsky HH, Usami S, Chien S. In vivo measurements of ''apparent viscosity'' and microvessel hematocrit in the mesentery of the cat. Microvasc Res 1980; 19: 297-319.
16. Barbee JH, Cokelet GR. Prediction of blood flow in tubes with diameters as small as 29 microns. Microvasc Res 1971; 3: 17-21.
17. Pries AR, Neuhaus D, Gaehtgens P. Blood viscosity in tube flow: dependence on diameter and hematocrit. Am J Physiol 1992; 263 (Part 2): H1770-H1778.
18. Pries AR, Secomb TW. Microvascular blood viscosity in vivo and the endothelial surface layer. Am J Physiol Heart Circ Physiol 2005; 289: H2657-H2664.
19. Linderkamp O, Klose HJ, Betke K, et al. Increased blood viscosity in patients with cyanotic congenital heart disease and iron deficiency. J Pediatr 1979; 95: 567-569.
20. Hutton RD. The effect of iron deficiency on whole blood viscosity in polycythaemic patients. Br J Haematol 1979; 43: 191-199.
21. Milligan DW, MacNamee R, Roberts BE, Davies JA. The influence of iron-deficient indices on whole blood viscosity in polycythaemia. Br J Haematol 1982; 50: 467-471.
22. Pearson TC, Grimes AJ, Slater NG, Wetherley-Mein G. Viscosity and iron deficiency in treated polycythaemia. Br J Haematol 1981; 49: 123-127.
23. Van de Pette JE, Guthrie DL, Pearson TC. Whole blood viscosity in polycythaemia: the effect of iron deficiency at a range of haemoglobin and packed cell volumes. Br J Haematol 1986; 63: 369-375.
24. Broberg CS, Bax BE, Okonko DO, et al. Blood viscosity and its relationship to iron deficiency, symptoms, and exercise capacity in adults with cyanotic congenital heart disease. J Am Coll Cardiol 2006; 48: 356-365.
25. Iolster NJ. Blood coagulation in children with cyanotic congenital heart disease. Acta Paediatr Scand 1970; 59: 551-557.
26. Martelle RR, Linde LM. Cerebrovascular accidents with tetralogy of Fallot. Am J Dis Child 1961; 101: 206-209.
27. Maguire JL, deVeber G, Parkin PC. Association between irondeficiency anemia and stroke in young children. Pediatrics 2007; 120: 1053-1057.
28. Koller A, Sun D, Kaley G. Role of shear stress and endothelial prostaglandins in flow- and viscosity-induced dilation of arterioles in vitro. Circ Res 1993; 72: 1276-1284.
29. Tsai AG, Friesenecker B, McCarthy M, Sakai H, Intaglietta M. Plasma viscosity regulates capillary perfusion during extreme hemodilution in hamster skinfold model. Am J Physiol 1998; 275 (Part 2): H2170-H2180.
30. Hudak ML, Jones MD Jr, Popel AS, Koehler RC, Traystman RJ, Zeger SL. Hemodilution causes size-dependent constriction of pial arterioles in the cat. Am J Physiol 1989; 257 (Part 2): H912-H917.
31. Cabrales P, Tsai AG. Plasma viscosity regulates systemic and microvascular perfusion during acute extreme anemic conditions. Am J Physiol Heart Circ Physiol 2006; 291: H2445-H2452.
32. Tsai AG, Acero C, Nance PR, et al. Elevated plasma viscosity in extreme hemodilution increases perivascular nitric oxide concentration and microvascular perfusion. Am J Physiol Heart Circ Physiol 2005; 288: H1730-H1739.
33. Cooke JP, Stamler J, Andon N, Davies PF, McKinley G, Loscalzo J. Flow stimulates endothelial cells to release a nitrovasodilator that is potentiated by reduced thiol. Am J Physiol 1990; 259 (Part 2): H804-H812.
34. Pohl U, Herlan K, Huang A, Bassenge E. EDRF-mediated shearinduced dilation opposes myogenic vasoconstriction in small rabbit arteries. Am J Physiol 1991; 261 (Part 2): H2016-H2023.
35. Celermajer DS, Sorensen KE, Gooch VM, et al. Non-invasive detection of endothelial dysfunction in children and adults at risk of atherosclerosis. Lancet 1992; 340: 1111-1115.
36. de Wit C, Schafer C, von Bismarck P, Bolz SS, Pohl U. Elevation of plasma viscosity induces sustained NO-mediated dilation in the hamster cremaster microcirculation in vivo. Pflugers Arch 1997; 434: 354-361.
37. Wilcox CS, Deng X, Doll AH, Snellen H, Welch WJ. Nitric oxide mediates renal vasodilation during erythropoietin-induced polycythemia. Kidney Int 1993; 44: 430-435.
38. Lopez Ongil SL, Saura M, Lamas S, Rodriguez Puyol M, Rodriguez Puyol D. Recombinant human erythropoietin does not regulate the expression of endothelin-1 and constitutive nitric oxide synthase in vascular endothelial cells. Exp Nephrol 1996; 4: 37-42.
39. Wang XQ, Vaziri ND. Erythropoietin depresses nitric oxide synthase expression by human endothelial cells. Hypertension 1999; 33: 894-899.
40. Gidding SS, Stockman JA 3rd. Erythropoietin in cyanotic heart disease. Am Heart J 1988; 116 (Part 1): 128-132.
41. Tyndall MR, Teitel DF, Lutin WA, Clemons GK, Dallman PR. Serum erythropoietin levels in patients with congenital heart disease. J Pediatr 1987; 110: 538-544.
42. Ogunshola OO, Djonov V, Staudt R, Vogel J, Gassmann M. Chronic excessive erythrocytosis induces endothelial activation and damage in mouse brain. Am J Physiol Regul Integr Comp Physiol 2006; 290: R678-R684.
43. Belhassen L, Pelle G, Sediame S, et al. Endothelial dysfunction in patients with sickle cell disease is related to selective impairment of shear stress-mediated vasodilation. Blood 2001; 97: 1584-1589.
44. Gillespie JS, Sheng H. Influence of haemoglobin and erythrocytes on the effects of EDRF, a smooth muscle inhibitory factor, and nitric oxide on vascular and non-vascular smooth muscle. Br J Pharmacol 1988; 95: 1151-1156.
45. Rimar S, Gillis CN. Selective pulmonary vasodilation by inhaled nitric oxide is due to hemoglobin inactivation. Circulation 1993; 88: 2884-2887.
46. Rich GF, Roos CM, Anderson SM, Urich DC, Daugherty MO, Johns RA. Inhaled nitric oxide: dose response and the effects of blood in the isolated rat lung. J Appl Physiol 1993; 75: 1278-1284.
47. Madsen PL, Scheuermann Freestone M, Neubauer S, Channon K, Clarke K. Haemoglobin and flow-mediated vasodilation. Clin Sci (Lond) 2006; 110: 467-473.
48. Anand IS, Chandrashekhar Y, Wander GS, Chawla LS. Endothelium- derived relaxing factor is important in mediating the high output state in chronic severe anemia. J Am Coll Cardiol 1995; 25: 1402-1407.
49. Defouilloy C, Teiger E, Sediame S, et al. Polycythemia impairs vasodilator response to acetylcholine in patients with chronic hypoxemic lung disease. Am J Respir Crit Care Med 1998; 157 (Part 1): 1452-1460.
50. Giannattasio C, Piperno A, Failla M, Vergani A, Mancia G. Effects of hematocrit changes on flow-mediated and metabolic vasodilation in humans. Hypertension 2002; 40: 74-77.
51. Oldershaw PJ, Sutton MG. Haemodynamic effects of haematocrit reduction in patients with polycythaemia secondary to cyanotic congenital heart disease. Br Heart J 1980; 44: 584-588.
52. Rosenthal A, Nathan DG, Marty AT, Button LN, Miettinen OS, Nadas AS. Acute hemodynamic effects of red cell volume reduction in polycythemia of cyanotic congenital heart disease. Circulation 1970; 42: 297-308.
53. Gladwin MT, Lancaster JR Jr, Freeman BA, Schechter AN. Nitric oxide's reactions with hemoglobin: a view through the SNOstorm. Nat Med 2003; 9: 496-500.
54. Gross SS, Lane P. Physiological reactions of nitric oxide and hemoglobin: a radical rethink. Proc Natl Acad Sci USA 1999; 96: 9967-9969.
55. Han TH, Pelling A, Jeon TJ, Gimzewski JK, Liao JC. Erythrocyte nitric oxide transport reduced by a submembrane cytoskeletal barrier. Biochim Biophys Acta 2005; 1723: 135-142.
56. Liu X, Samouilov A, Lancaster JR Jr, Zweier JL. Nitric oxide uptake by erythrocytes is primarily limited by extracellular diffusion not membrane resistance. J Biol Chem 2002; 277: 26194-26199.
57. Liao JC, Hein TW, Vaughn MW, Huang KT, Kuo L. Intravascular flow decreases erythrocyte consumption of nitric oxide. Proc Natl Acad Sci U S A 1999; 96: 8757-8761.
58. Kim-Shapiro DB, Schechter AN, Gladwin MT. Unraveling the reactions of nitric oxide, nitrite, and hemoglobin in physiology and therapeutics. Arterioscler Thromb Vasc Biol 2006; 26: 697-705.
59. Bonetti PO, Pumper GM, Higano ST, Holmes Jr DR, Kuvin JT, Lerman A. Noninvasive identification of patients with early coronary atherosclerosis by assessment of digital reactive hyperemia. J Am Coll Cardiol 2004; 44: 2137-2141.
60. Andreassen AK, Kvernebo K, Jorgensen B, Simonsen S, Kjekshus J, Gullestad L. Exercise capacity in heart transplant recipients: relation to impaired endothelium-dependent vasodilation of the peripheral microcirculation. Am Heart J 1998; 136: 320-328.
61. Katz SD, Hryniewicz K, Hriljac I, et al. Vascular endothelial dysfunction and mortality risk in patients with chronic heart failure. Circulation 2005; 111: 310-314.
62. Pohl U, Holtz J, Busse R, Bassenge E. Crucial role of endothelium in the vasodilator response to increased flow in vivo. Hypertension 1986; 8: 37-44.
63. Ramsey MW, Goodfellow J, Jones CJ, Luddington LA, Lewis MJ, Henderson AH. Endothelial control of arterial distensibility is impaired in chronic heart failure. Circulation 1995; 92: 3212-3219.
64. Maiorana A, O'Driscoll G, Dembo L, et al. Effect of aerobic and resistance exercise training on vascular function in heart failure. Am J Physiol Heart Circ Physiol 2000; 279: H1999-H2005.
65. Hambrecht R, Hilbrich L, Erbs S, et al. Correction of endothelial dysfunction in chronic heart failure: additional effects of exercise training and oral L-arginine supplementation. J Am Coll Cardiol 2000; 35: 706-713.
66. Adatia I, Kemp GJ, Taylor DJ, Radda GK, Rajagopalan B, Haworth SG. Abnormalities in skeletal muscle metabolism in cyanotic patients with congenital heart disease: a 31P nuclear magnetic resonance spectroscopy study. Clin Sci (Lond) 1993; 85: 105-109.
67. Miall-Allen VM, Kemp GJ, Rajagopalan B, Taylor DJ, Radda GK, Haworth SG. Magnetic resonance spectroscopy in congenital heart disease. Heart 1996; 75: 614-619.
68. Oechslin E, Kiowski W, Schindler R, Bernheim A, Julius B, Brunner-La Rocca HP. Systemic endothelial dysfunction in adults with cyanotic congenital heart disease. Circulation 2005; 112: 1106-1112.
69. Ferreiro CR, Chagas AC, Carvalho MH, et al. Influence of hypoxia on nitric oxide synthase activity and gene expression in children with congenital heart disease: a novel pathophysiological adaptive mechanism. Circulation 2001; 103: 2272-2276.
70. Toporsian M, Govindaraju K, Nagi M, Eidelman D, Thibault G, Ward ME. Downregulation of endothelial nitric oxide synthase in rat aorta after prolonged hypoxia in vivo. Circ Res 2000; 86: 671-675.
71. Armstead WM. Opioids and nitric oxide contribute to hypoxiainduced pial arterial vasodilation in newborn pigs. Am J Physiol 1995; 268 (Part 2): H226-H232.
72. Nase GP, Tuttle J, Bohlen HG. Reduced perivascular PO2 increases nitric oxide release from endothelial cells. Am J Physiol Heart Circ Physiol 2003; 285: H507-H515.
73. Pape D, Beuchard J, Guillo P, Allain H, Bellissant E. Hypoxic contractile response in isolated rat thoracic aorta: role of endothelium, extracellular calcium and endothelin. Fundam Clin Pharmacol 1997; 11: 121-126.
74. Wolff B, Lodziewski S, Bollmann T, Opitz CF, Ewert R. Impaired peripheral endothelial function in severe idiopathic pulmonary hypertension correlates with the pulmonary vascular response to inhaled iloprost. Am Heart J 2007; 153: 1088 e1-7.
75. Karakantza M, Giannakoulas NC, Zikos P, et al. Markers of endothelial and in vivo platelet activation in patients with essential thrombocythemia and polycythemia vera. Int J Hematol 2004; 79: 253-259.
76. Lessiani G, Dragani A, Falco A, Fioritoni F, Santilli F, Davi G. Soluble CD40 ligand and endothelial dysfunction in aspirintreated polycythaemia vera patients. Br J Haematol 2009; 145: 538-540.
77. Neunteufl T, Heher S, Stefenelli T, Pabinger I, Gisslinger H. Endothelial dysfunction in patients with polycythaemia vera. Br J Haematol 2001; 115: 354-359.
78. Michiels C, Arnould T, Remacle J. Endothelial cell responses to hypoxia: initiation of a cascade of cellular interactions. Biochim Biophys Acta 2000; 1497: 1-10.
79. Ten VS, Pinsky DJ. Endothelial response to hypoxia: physiologic adaptation and pathologic dysfunction. Curr Opin Crit Care 2002; 8: 242-250.
80. Malek AM, Jackman R, Rosenberg RD, Izumo S. Endothelial expression of thrombomodulin is reversibly regulated by fluid shear stress. Circ Res 1994; 74: 852-860.
81. Horigome H, Murakami T, Isobe T, Nagasawa T, Matsui A. Soluble P-selectin and thrombomodulin-protein C-Protein S pathway in cyanotic congenital heart disease with secondary erythrocytosis. Thromb Res 2003; 112: 223-227.
82. Territo MC, Perloff JK, Rosove MH, Moake JL, Runge A. Acquired Von Willebrand factor abnormalities in adults with congenital heart disease: dependence upon cardiopulmonary pathophysiological subtype. Clin Appl Thromb Hemost 1998; 4: 257-261.
83. de PS Soares R, Maeda NY, Bydlowski SP, Lopes AA. Markers of endothelial dysfunction and severity of hypoxaemia in the Eisenmenger syndrome. Cardiol Young 2005; 15: 504-513.
84. Starnes SL, Duncan BW, Kneebone JM, et al. Vascular endothelial growth factor and basic fibroblast growth factor in children with cyanotic congenital heart disease. J Thorac Cardiovasc Surg 2000; 119: 534-539.
85. Niwa K, Perloff JK, Bhuta SM, et al. Structural abnormalities of great arterial walls in congenital heart disease: light and electron microscopic analyses. Circulation 2001; 103: 393-400.
86. Dedkov EI, Perloff JK, Tomanek RJ, Fishbein MC, Gutterman DD. The coronary microcirculation in cyanotic congenital heart disease. Circulation 2006; 114: 196-200.
87. Fyfe A, Perloff JK, Niwa K, Child JS, Miner PD. Cyanotic congenital heart disease and coronary artery atherogenesis. Am J Cardiol 2005; 96: 283-290.
88. Perloff JK. The coronary circulation in cyanotic congenital heart disease. Int J Cardiol 2004; 97 (Suppl 1): 79-86.
89. Mansour AM, Bitar FF, Traboulsi EI, et al. Ocular pathology in congenital heart disease. Eye 2005; 19: 29-34.
90. Petersen RA, Rosenthal A. Retinopathy and papilledema in cyanotic congenital heart disease. Pediatrics 1972; 49: 243-249.
91. Chugh R, Perloff JK, Fishbein M, Child JS. Extramural coronary arteries in adults with cyanotic congenital heart disease. Am J Cardiol 2004; 94: 1355-1357.
92. Crowe RJ, Kohner EM, Owen SJ, Robinson DM. The retinal vessels in congenital cyanotic heart disease. Med Biol Illus 1969; 19: 95-99.
93. Kohner EM, Allen EM, Saunders KB, Emery VM, Pallis C. Electroencephalogram and retinal vessels in congenital cyanotic heart disease before and after surgery. BMJ 1967; 4: 207-210.
94. Harino S, Motokura M, Nishikawa N, Fukuda M, Sasaoka A, Grunwald JE. Chronic ocular ischemia associated with the Eisenmenger's syndrome. Am J Ophthalmol 1994; 117: 302-307.
95. Eperon G, Johnson M, David NJ. The effect of arterial PO2 on relative retinal blood flow in monkeys. Invest Ophthalmol 1975; 14: 342-352.
96. Ames A 3rd. Energy requirements of CNS cells as related to their function and to their vulnerability to ischemia: a commentary based on studies on retina. Can J Physiol Pharmacol 1992; 70 (Suppl): S158-S164.
97. Ahmed J, Pulfer MK, Linsenmeier RA. Measurement of blood flow through the retinal circulation of the cat during normoxia and hypoxemia using fluorescent microspheres. Microvasc Res 2001; 62: 143-153.
98. Bosch MM, Merz TM, Barthelmes D, et al. New insights into ocular blood flow at very high altitudes. J Appl Physiol 2009; 106: 454-460.
99. Wangsa-Wirawan ND, Linsenmeier RA. Retinal oxygen: fundamental and clinical aspects. Arch Ophthalmol 2003; 121: 547-557.
100. Linsenmeier RA, Braun RD. Oxygen distribution and consumption in the cat retina during normoxia and hypoxemia. J Gen Physiol 1992; 99: 177-197.
101. Bosch MM, Barthelmes D, Merz TM, et al. High incidence of optic disc swelling at very high altitudes. Arch Ophthalmol 2008; 126: 644-650.
102. Rennie D, Morrissey J. Retinal changes in Himalayan climbers. Arch Ophthalmol 1975; 93: 395-400.
103. Wiedman M. High altitude retinal hemorrhage. Arch Ophthalmol 1975; 93: 401-403.
104. Shults WT, Swan KC. High altitude retinopathy in mountain climbers. Arch Ophthalmol 1975; 93: 404-408.
105. Droma Y, Hanaoka M, Basnyat B, et al. Symptoms of acute mountain sickness in Sherpas exposed to extremely high altitude. High Alt Med Biol 2006; 7: 312-314.
106. Clarke C, Duff J. Mountain sickness, retinal haemorrhages, and acclimatisation on Mount Everest in 1975. BMJ 1976; 2: 495-497
107. Wilson MH, Newman S, Imray CH. The cerebral effects of ascent to high altitudes. Lancet Neurol 2009; 8: 175-191.
108. Hammond CJ, Chauhan DS, Stanford MS. Pulmonary hypertension and diffuse macular edema responsive to acetazolamide. Arch Ophthalmol 1998; 116: 1535-1536.
109. Van Camp G, Renard M, Verougstraete C, Bernard R. Ophthalmologic complications in primary pulmonary hypertension. Chest 1990; 98: 1543-1544.
110. Kety SS, Schmidt CF. The effects of altered arterial tensions of carbon dioxide and oxygen on cerebral blood flow and cerebral oxygen consumption of normal young men. J Clin Invest 1948; 27: 484-492.
111. Lennox WG, Gibbs EL. The blood flow in the brain and the leg of man, and the changes induced by alteration of blood gases. J Clin Invest 1932; 11: 1155-1177.
112. De Schweinitz GE, Woods AC. Concerning the ocular symptoms of erythremia (chronic polycythemia vera), with special reference to the fundus picture. Trans Am Ophthalmol Soc 1925; 23: 90-105.
113. Feman SS, Stein RS. Waldenstrom's macroglobulinemia, a hyperviscosity manifestation of venous stasis retinopathy. Int Ophthalmol 1981; 4: 107-112.
114. Nagy F. Changes in the fundus caused by polycythaemia. Br J Ophthalmol 1950; 34: 380-384.
115. Morley MG, Heier JS. Venous obstructive disease of the retina. In: Yanoff M, Duker JS (eds). Yanoff and Duker: Ophthalmology, 3rd edn. Mosby, St. Louis, MO, 2008; 597-601.
116. Tsutsumi A. Retinopathy in cyanotic congenital heart disease. Jpn J Clin Ophthalmol 1983; 37: 933.
117. Michelson G, Welzenbach J, Pal I, Harazny J. Functional imaging of the retinal microvasculature by scanning laser Doppler flowmetry. Int Ophthalmol 2001; 23: 327-335.
118. Michelson G, Patzelt A, Harazny J. Flickering light increases retinal blood flow. Retina 2002; 22: 336-343.
119. Wong TY, Islam FM, Klein R, et al. Retinal vascular caliber, cardiovascular risk factors, and inflammation: the multi-ethnic study of atherosclerosis (MESA). Invest Ophthalmol Vis Sci 2006; 47: 2341-2350.
120. Klein R, Klein BE, Knudtson MD, Wong TY, Tsai MY. Are inflammatory factors related to retinal vessel caliber? The Beaver Dam eye study. Arch Ophthalmol 2006; 124: 87-94. (Pubitemid 43063893)
121. Ikram MK, de Jong FJ, Vingerling JR, et al. Are retinal arteriolar or venular diameters associated with markers for cardiovascular disorders? The Rotterdam Study. Invest Ophthalmol Vis Sci 2004; 45: 2129-2134.
122. Wong TY, Kamineni A, Klein R, et al. Quantitative retinal venular caliber and risk of cardiovascular disease in older persons: the cardiovascular health study. Arch Intern Med 2006; 166: 2388-2394.
123. Wong TY, Klein R, Sharrett AR, et al. Retinal arteriolar narrowing and risk of coronary heart disease in men and women. The atherosclerosis risk in communities study. JAMA 2002; 287: 1153-1159.
124. Wong TY, Klein R, Couper DJ, et al. Retinal microvascular abnormalities and incident stroke: the Atherosclerosis risk in communities study. Lancet 2001; 358: 1134-1140.
125. Wang JJ, Liew G, Wong TY, et al. Retinal vascular calibre and the risk of coronary heart disease-related death. Heart 2006; 92: 1583-1587.
126. Wong TY, Klein R, Nieto FJ, et al. Retinal microvascular abnormalities and 10-year cardiovascular mortality: a populationbased case-control study. Ophthalmology 2003; 110: 933-940. (Pubitemid 36560492)
127. Kawagishi T, Matsuyoshi M, Emoto M, et al. Impaired endothelium-dependent vascular responses of retinal and intrarenal arteries in patients with type 2 diabetes. Arterioscler Thromb Vasc Biol 1999; 19: 2509-2516.
128. Delles C, Michelson G, Harazny J, Oehmer S, Hilgers KF, Schmieder RE. Impaired endothelial function of the retinal vasculature in hypertensive patients. Stroke 2004; 35: 1289-1293.
129. Hida K, Wada J, Yamasaki H, et al. Cyanotic congenital heart disease associated with glomerulomegaly and focal segmental glomerulosclerosis: remission of nephrotic syndrome with angiotensin converting enzyme inhibitor. Nephrol Dial Transplant 2002; 17: 144-147.
130. Fujimoto Y, Matsushima M, Tsuzuki K, et al. Nephropathy of cyanotic congenital heart disease: clinical characteristics and effectiveness of an angiotensin-converting enzyme inhibitor. Clin Nephrol 2002; 58: 95-102.
131. Fujita N, Manabe H, Yoshida N, et al. Inhibition of angiotensin- converting enzyme protects endothelial cell against hypoxia/reoxygenation injury. Biofactors 2000; 11: 257-266.
132. Walther T, Olah L, Harms C, et al. Ischemic injury in experimental stroke depends on angiotensin II. FASEB J 2002; 16: 169-176.
133. Creager MA, Roddy MA. Effect of captopril and enalapril on endothelial function in hypertensive patients. Hypertension 1994; 24: 499-505.
134. O'Driscoll G, Green D, Maiorana A, Stanton K, Colreavy F, Taylor R. Improvement in endothelial function by angiotensinconverting enzyme inhibition in non-insulin-dependent diabetes mellitus. J Am Coll Cardiol 1999; 33: 1506-1511.
135. Glynn RJ, Danielson E, Fonseca FA, et al. A randomized trial of rosuvastatin in the prevention of venous thromboembolism. N Engl J Med 2009; 360: 1851-1861.
136. Phornphutkul C, Rosenthal A, Nadas AS, Berenberg W. Cerebrovascular accidents in infants and children with cyanotic congenital heart disease. Am J Cardiol 1973; 32: 329-334.